269 related articles for article (PubMed ID: 21812499)
21. Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.
Jonasch E; Signorovitch JE; Lin PL; Liu Z; Culver K; Pal SK; Scott JA; Vogelzang NJ
Curr Med Res Opin; 2014 Oct; 30(10):2041-50. PubMed ID: 24983741
[TBL] [Abstract][Full Text] [Related]
22. Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies.
Bastin J; Werbrouck E; Verbiest A; Punie K; Bechter O; Woei-A-Jin FJ; Wolter P; Wildiers H; Lerut E; Dumez H; Decallonne B; Clement P; Vanderschueren D; Albersen M; Oyen R; Schöffski P; Beuselinck B
Acta Clin Belg; 2019 Jun; 74(3):169-179. PubMed ID: 29774795
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy and targeted therapies in metastatic renal cell carcinoma: is there a preferred sequence?
Giuliani J; Drudi F
Cancer Biother Radiopharm; 2012 Oct; 27(8):513-8. PubMed ID: 22738404
[TBL] [Abstract][Full Text] [Related]
24. Assessment of Treatment Patterns for Metastatic Renal Cell Carcinoma in Brazil.
Bergerot PG; Bergerot CD; Dizman N; Zequi S; Fay A; Dara Y; Maia MC; Cotta BN; Gonçalves EP; Formiga MN; Tariki MS; Clavijo DA; Choueiri TK; Lopes G; Pal SK
J Glob Oncol; 2018 Sep; 4():1-8. PubMed ID: 29281478
[TBL] [Abstract][Full Text] [Related]
25. A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.
Albiges L; Choueiri T; Escudier B; Galsky M; George D; Hofmann F; Lam T; Motzer R; Mulders P; Porta C; Powles T; Sternberg C; Bex A
Eur Urol; 2015 Jan; 67(1):100-110. PubMed ID: 24841777
[TBL] [Abstract][Full Text] [Related]
26. Renal cell carcinoma: molecular biology and targeted therapy.
Su D; Stamatakis L; Singer EA; Srinivasan R
Curr Opin Oncol; 2014 May; 26(3):321-7. PubMed ID: 24675233
[TBL] [Abstract][Full Text] [Related]
27. Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland.
Sandmeier N; Rothschild SI; Rothermundt C; Cathomas R; Schardt J; Berthold D; von Burg P; Müller B; Beyer J; Vogt DR; Stenner F
Clin Genitourin Cancer; 2018 Aug; 16(4):e711-e718. PubMed ID: 29503245
[TBL] [Abstract][Full Text] [Related]
28. Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies.
Heng DY; Signorovitch J; Swallow E; Li N; Zhong Y; Qin P; Zhuo DY; Wang X; Park J; Stergiopoulos S; Kollmannsberger C
PLoS One; 2014; 9(12):e114264. PubMed ID: 25493562
[TBL] [Abstract][Full Text] [Related]
29. Management of adverse events of targeted therapies in normal and special patients with metastatic renal cell carcinoma.
Méndez-Vidal MJ; Martínez Ortega E; Montesa Pino A; Pérez Valderrama B; Viciana R
Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S19-27. PubMed ID: 22821550
[TBL] [Abstract][Full Text] [Related]
30. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.
Ainsworth NL; Lee JS; Eisen T
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.
Raman R; Vaena D
Biomed Res Int; 2015; 2015():367354. PubMed ID: 26161397
[TBL] [Abstract][Full Text] [Related]
32. Perioperative approaches to kidney cancer.
Iheanacho K; Vaishampayan U
Clin Adv Hematol Oncol; 2020 Jan; 18(1):56-65. PubMed ID: 32511222
[TBL] [Abstract][Full Text] [Related]
33. Kidney cancer: Low serum sodium linked to poor outcomes for patients with mRCC treated with targeted therapy.
Clyne M
Nat Rev Urol; 2013 Dec; 10(12):679. PubMed ID: 24217674
[No Abstract] [Full Text] [Related]
34. Optimal management of metastatic renal cell carcinoma: current status.
Escudier B; Albiges L; Sonpavde G
Drugs; 2013 Apr; 73(5):427-38. PubMed ID: 23572408
[TBL] [Abstract][Full Text] [Related]
35. Significance of Age in Japanese Patients Receiving Sunitinib as First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: Comparative Assessment of Efficacy and Safety between Patients Aged <75 and ≥75 Years.
Miyake H; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Anticancer Res; 2018 Jun; 38(6):3593-3599. PubMed ID: 29848715
[TBL] [Abstract][Full Text] [Related]
36. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Oudard S; Elaidi RT
Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
[TBL] [Abstract][Full Text] [Related]
37. Advances in treatment of metastatic renal cell carcinoma.
Gong J; Gerendash B; Dizman N; Khan A; Pal SK
Curr Opin Urol; 2016 Sep; 26(5):439-46. PubMed ID: 27467136
[TBL] [Abstract][Full Text] [Related]
38. Current and Emerging Treatments for Metastatic Renal Cell Carcinoma.
Cavaliere C; D'Aniello C; Pepa CD; Pisconti S; Berretta M; Facchini G
Curr Cancer Drug Targets; 2018; 18(5):468-479. PubMed ID: 28183256
[TBL] [Abstract][Full Text] [Related]
39. Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC).
Seidel C; Busch J; Weikert S; Steffens S; Bokemeyer C; Grünwald V
Br J Cancer; 2013 Dec; 109(12):2998-3004. PubMed ID: 24169357
[TBL] [Abstract][Full Text] [Related]
40. The role of targeted therapy in metastatic renal cell carcinoma.
Unnithan J; Rini BI
ScientificWorldJournal; 2007 Mar; 7():800-7. PubMed ID: 17619763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
